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A preformulated chikungunya virus real-time reverse 
transcription–PCR, quality-confi rmed oligonucleotides, and 
noninfectious virus controls were distributed by the Europe-
an Network for the Diagnosis of Imported Viral Diseases. An 
international profi ciency study with 31 participants demon-
strated that ad hoc implementation of molecular diagnostics 
was feasible and successful.
Chikungunya fever, caused by chikungunya virus (CHIKV), is an acute febrile illness that causes severe 
and long-lasting arthralgia (1). A recent and ongoing epi-
demic in the Indian Ocean area extended far beyond this 
region and caused hundreds of imported cases worldwide 
(2–4). Chikungunya fever is diffi cult to clinically distin-
guish from co-endemic diseases such as malaria or dengue 
fever. Laboratory testing is required for appropriate case 
management and public health response (5). Pilot studies 
have shown that reverse transcription–PCR (RT-PCR) re-
liably detects acute infections in humans (3,6), but many 
laboratories were not ready to conduct such tests when this 
epidemic occurred.
During 2006 and 2007, the European Network for 
the Diagnosis of Imported Viral Diseases (ENIVD) re-
ceived requests by many laboratories for assistance with 
CHIKV diagnostics. On the basis of experiences during 
the outbreak of severe acute respiratory syndrome (SARS) 
in 2003 (7), an ENIVD member laboratory distributed a 
then-unpublished real-time RT-PCR protocol that had been 
evaluated with a large number of clinical samples from im-
ported cases to laboratories asking for assistance (3). To 
determine effi cacy of RT-PCR testing for CHIKV, we dis-
tributed testing materials to 31 participating laboratories in 
an external quality assurance study. Laboratories sent their 
results to ENIVD for analysis of effi cacy.
The Study
Information distributed to laboratories asking for as-
sistance with CHIKV RT-PCR included reaction chemis-
try setup, cycling profi le, and primer and probe sequences. 
A quantifi ed CHIKV in vitro RNA transcript containing 9 
× 1010 subgenomic RNA copies/μL was used as a nonin-
fectious positive control. Additional measures were taken 
to provide proper primers and probes because these com-
ponents are most vulnerable to variation when assays are 
adapted from protocols, e.g., because of synthesis errors or 
poor purifi cation. Primers and probes were synthesized in 
large reference lots and stored centrally at an oligonucle-
otide factory. Samples of these lots were validated by the 
reference laboratory and confi rmed to provide full sensitiv-
ity as achieved with the original primers used in develop-
ing the prototype assay (3). Recipients of protocols were 
invited to order and use aliquots of primers directly from 
the validated reference lot.
To receive feedback on performance of this method 
and other methods of CHIKV detection, a profi ciency study 
was organized among ENIVD members. All participants 
were informed about the option of obtaining the preformu-
lated assay. Laboratories in Europe (22), Asia (6), South 
America (2), and Africa (1) participated.
Inactivated and stable testing material was generated 
from cell culture supernatants of 4 CHIKV strains from the 
epidemic in the Indian Ocean area (1 each from Seychelles, 
Mauritius, Réunion Island, and India) and 1 East/Central 
Africa strain (S27). Virus solutions were inactivated by 
heating at 56°C for 1 h and gamma irradiation with 30 kGy. 
Residual infectivity was excluded by 3 blind passages of 
a sample of each solution on Vero cells. Solutions were 
diluted in human fresh-frozen plasma, aliquoted (100 μL), 
and lyophilized. Test aliquots were reconstituted in 100 μL 
of water, and CHIKV RNA was quantifi ed by RT-PCR (3). 
Lyophilized samples were shipped at ambient temperature 
to participating laboratories. Each shipment contained a 
coded panel of 9 CHIKV RNA positive– and 3 CHIKV 
RNA–negative lyophilized samples with virus concentra-
tions shown in Table 1. Participants were asked to test the 
material with any molecular assay routinely used for de-
tecting CHIKV in human plasma or with the preformulated 
test. We requested test results and assay details (PCR for-
mulations and extraction methods). A total of 36 sets of 
results were received by the study coordinator, including 3 
double sets from 3 laboratories that used 2 methods each. 
One laboratory provided triple sets of results from 3 tests.
We used 2 criteria to defi ne successful participation in 
the external quality assessment study. First, those samples 
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containing >7,040 RNA copies/mL should be correctly 
identifi ed. Analogous to previous external quality assess-
ments (8–11), we chose this threshold because it is ≈5–10× 
above the limit of detection of current CHIKV RT-PCR 
protocols (3,12). Second, no false-positive results were al-
lowed in virus-free samples.
Samples containing 10,487,171 RNA copies/mL were 
correctly detected by all participating laboratories (Table 
1). Fifteen (48%) of the laboratories were able to detect 
samples containing >7,040 RNA copies/mL. Only 22.6% 
correctly detected the sample with 1,076 copies/mL. Of 31 
laboratories, 14 (45.2%) met all profi ciency criteria. Sev-
enteen laboratories missed the profi ciency criteria because 
of a lack of sensitivity. Two of these laboratories reported 
>1 false-positive result. Both laboratories had used a nested 
RT-PCR, which likely indicated cross-contamination dur-
ing RT-PCR procedures. No other laboratories reported 
false-positive results.
To project performance of a hypothetical average labo-
ratory, cumulative fractions of positive results reported for 
each test sample were correlated against RNA concentra-
tions in samples and subjected to probit analysis. This pro-
cedure used a dose-response model, which predicted for the 
average laboratory that a 50% certainty of detection was 
achieved for CHIKV plasma concentrations >10,000 RNA 
copies/mL (95% confi dence interval [CI] 3,162–19,952 
copies/mL) (Figure). A 95% certainty of detection was 
achieved for CHIKV plasma concentrations >7,943,282 
copies/mL (95% CI 2,511,886–39,810,717 copies/mL).
To evaluate critical criteria in laboratory practice, we 
determined whether particular components of laboratory 
procedures had any systematic infl uence on laboratory per-
formance. Selection of criteria was based on experiences 
from earlier external quality assessment studies (8,9,11). 
We evaluated automated versus manual RNA extraction 
methods, 1 widely distributed procedure for RNA extrac-
tion (viral RNA mini kit; QIAGEN, Hilden, Germany), any 
real-time RT-PCR, any nested RT-PCR, or the preformu-
lated RT-PCR distributed with this study. Cumulative frac-
tional positive results of all low- and medium-concentration 
samples (<86,197 copies/mL) were subjected to multifactor 
analysis of variance, which eliminated infl uence of other 
defi ned factors in each analysis. The only technical factor 
that increased sensitivity was the preformulated RT-PCR 
(Table 2). Thirteen (42%) of 31 participants used this as-
say. Another factor with nonsignifi cant benefi t (p = 0.08) 
was use of automated RNA extraction.
Conclusions
Because of little disease activity before the epidemic, 
laboratories inside and outside epidemic regions were not 
prepared to detect CHIKV when the epidemic occurred. In 
a similar situation during the SARS epidemic in 2003, we 
demonstrated that rapid provision of a commercial test kit 
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Table 1. Positive samples in external quality assessment panel 
for detection of CHIKV by reverse transcription–PCR* 
Sample







CHIK #2 Réunion Island 10,487,171 100
CHIK #9 Réunion Island 745,257 77.4
CHIK #4 Réunion Island 86,197 83.9
CHIK #12 Réunion Island 7,040 48.4
CHIK #5 Réunion Island 1,076 22.6
CHIK #6 India 918,259 96.8
CHIK #10 Seychelles 526,268 87.1
CHIK #1 Mauritius 564,192 83.9
CHIK #11 East Africa 1,131,422 87.1
*CHIKV, chikungunya virus. 
Figure. Probit analysis of laboratories with a positive result (y axes) 
for chikungunya virus in relation to viral RNA concentration in 
positive samples (x axes). A) Laboratories using in-house reverse 
transcription–PCRs (RT-PCRs) (n = 18) had a 50% certainty of 
having a positive result at 10,000 RNA copies/mL (95% confi dence 
interval [CI] 3,162–19,952). B) Laboratories using a preformulated 
RT-PCR (n = 13) had a 50% certainty of having a positive result at 
1,288 RNA copies/mL (95% CI 416–2,344). Data points represent 
individual samples in the test panel. Thick line is the regression line 
calculated on the basis of a probit model (dose-response curve), 
and thin lines are 95% CIs. Data fi t into the model with p<0.00001.
Chikungunya Virus RT-PCR
could greatly assist laboratories worldwide, enabling them 
to perform state-of-the art molecular diagnostics during the 
epidemic (7,9). However, for chikungunya fever, commer-
cial fi rms did not rapidly prioritize development of CHIKV 
test kits. ENIVD attempted to assist implementation of 
molecular diagnostics on an ad hoc basis by distributing a 
validated CHIKV RT-PCR and all required reagents.
Our profi ciency study showed surprisingly good over-
all performance of participating laboratories than most of 
our previous external quality assessments (8,10). Analysis 
of factors identifi ed that this success was primarily due 
to the preformulated assay. In our earlier external quality 
assessments on detection of emerging viruses, many par-
ticipants used diagnostic methods reported in the literature, 
which did not provide technical features such as real-time 
PCR (8,9,11). The assay distributed in this study was tech-
nically advanced, and its effi cient adaptation was supported 
by providing quality-controlled oligonucleotides and con-
trols. This in-house assay was readily implemented by a 
large number of laboratories. It improved diagnostic pro-
fi ciency similar to the commercial assay distributed during 
the SARS epidemic (9). We showed that novel PCR diag-
nostics for emerging diseases can be implemented on an 
international scale. However, enhanced support by refer-
ence laboratories through effi cient collaborative networks 
of laboratories is indispensable. Public health organizations 
should be encouraged by these data to strengthen and ex-
tend networking between diagnostic laboratory facilities.
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Table 2. Possible technical factors influencing performance of laboratories in detection of CHIKV* 
Factor No. laboratories p value for positive influence on sensitivity 
QIAGEN† viral RNA extraction kit 23 0.2
Any automated RNA extraction procedure 8 0.08
Preformulated CHIKV real-time RT-PCR protocol 13 0.03
Any real-time CHIKV RT-PCR 27 0.3
Any nested CHIKV RT-PCR 6 0.37
*CHIKV, chikungunya virus; RT-PCR, reverse transcription–PCR. 
†Hilden, Germany. 
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